Home » Biotechnology » Australia Stem Cell Contract Manufacturing Market

Australia Stem Cell Contract Manufacturing Market By Scale of Operation (Commercial, Clinical, Preclinical); By Size of Contract Manufacturer (Large/Very Large, Mid-sized, Small-sized); By Source of Stem Cells (Allogenic, Autologous); By Type of Stem Cells (Adult Stem Cells (ASCs), Human Embryonic Stem Cells (HESCs), Induced Pluripotent Stem Cells (iPSCs)); By End-user (Biopharmaceutical Companies, Research Institutes, Others) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Price: $2699

Published: | Report ID: 71812 | Report Format : PDF
REPORT ATTRIBUTE DETAILS
Historical Period 2019-2022
Base Year 2023
Forecast Period 2024-2032
Australia Stem Cell Contract Manufacturing MarketSize 2024 USD 22.27 million
Australia Stem Cell Contract Manufacturing Market, CAGR 13.25%
Australia Stem Cell Contract Manufacturing Market Size 2032  USD 60.24 million

Market Overview:

The Australia Stem Cell Contract Manufacturing Market is projected to grow from USD 22.27 million in 2024 to an estimated USD 60.24 million by 2032, with a compound annual growth rate (CAGR) of 13.25% from 2024 to 2032.

Several factors are propelling the growth of the stem cell contract manufacturing market in Australia. A key driver is the increasing prevalence of chronic and degenerative diseases such as diabetes, cardiovascular conditions, and neurodegenerative disorders, which have amplified the demand for innovative stem cell therapies. Supportive government initiatives, including funding programs and regulatory frameworks, have streamlined the development and commercialization of stem cell-based products. Additionally, Australia’s strong research and development ecosystem, bolstered by collaborations between academic institutions, biotech firms, and contract manufacturers, fosters a conducive environment for market growth. The shift toward personalized medicine and the integration of advanced bioprocessing technologies are further enhancing production efficiency and scalability in stem cell manufacturing.

Australia’s strategic positioning within the Asia-Pacific region makes it a hub for stem cell research and manufacturing. Key cities such as Sydney, Melbourne, and Brisbane are home to cutting-edge research facilities and biotech hubs, which contribute significantly to the market’s development. The country benefits from a highly skilled workforce, advanced infrastructure, and favorable policies that attract global investors and partnerships. Australia’s proactive stance on ethical practices and stringent regulatory standards ensures the production of high-quality stem cell products, bolstering its reputation on the global stage. Moreover, the increasing focus on international collaborations with markets in Asia, Europe, and North America is expected to drive sustained growth and enhance the country’s competitive advantage in stem cell contract manufacturing.

Design Element 2

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

CTA Design Element 3

Market Insights:

  • The market is projected to grow from USD 22.27 million in 2024 to USD 60.24 million by 2032, registering a compound annual growth rate (CAGR) of 13.25%, driven by increasing demand for stem cell therapies addressing chronic and degenerative diseases.
  • Supportive government policies, including funding programs and streamlined regulatory frameworks, are fostering innovation and enabling the commercialization of stem cell-based products.
  • Advanced bioprocessing technologies, such as automated cell culture systems and scalable bioreactors, are improving production efficiency, consistency, and scalability in stem cell manufacturing.
  • The shift toward personalized medicine is creating a strong demand for tailored stem cell therapies, particularly in oncology and regenerative medicine, enhancing the market’s growth potential.
  • Australia’s strategic position in the Asia-Pacific region, combined with cutting-edge research facilities in cities like Sydney, Melbourne, and Brisbane, reinforces its role as a global hub for stem cell research and manufacturing.
  • Challenges such as high manufacturing costs, stringent regulatory requirements, and a limited skilled workforce pose obstacles to market expansion, requiring industry collaboration and investment in talent development.
  • Growing international collaborations with markets in Asia, Europe, and North America are expanding Australia’s global presence and competitive edge in the stem cell contract manufacturing landscape.

Market Drivers:

Increasing Prevalence of Chronic and Degenerative Diseases

The growing burden of chronic and degenerative diseases, such as diabetes, neurodegenerative disorders, and cardiovascular conditions, is a significant driver for the Australia Stem Cell Contract Manufacturing Market. These diseases necessitate advanced therapeutic solutions, with stem cell therapies offering promising potential for treatment and management. For instance, Regeneus, an Australian biotechnology company, is developing stem cell therapies to treat inflammatory conditions and pain. As the aging population in Australia rises, the demand for innovative regenerative medicine is also increasing. Contract manufacturers play a critical role in meeting this demand by providing scalable and cost-effective solutions to biopharmaceutical companies developing stem cell-based therapies.

Supportive Government Policies and Investments

Australia’s government has implemented supportive policies and funding initiatives to foster growth in the stem cell contract manufacturing market. Programs such as the Medical Research Future Fund (MRFF) have allocated $150 million over nine years to support stem cell research and innovation. Regulatory frameworks, such as those established by the Therapeutic Goods Administration (TGA), streamline the approval process for new treatments while ensuring safety and quality. These measures encourage both domestic and international investments, creating a conducive environment for the market’s expansion.

Advancements in Bioprocessing Technologies

Technological advancements in bioprocessing are transforming stem cell manufacturing in Australia. Innovations such as automated cell culture systems, scalable bioreactors, and 3D bioprinting have enhanced production efficiency and consistency.  For example, researchers at the University of Technology Sydney have developed a 3D printed system for harvesting stem cells from bioreactors, which offers high-quality, wide-scale production at a lower cost. These technologies enable manufacturers to scale operations while maintaining high-quality standards, making therapies more accessible to patients. Additionally, the integration of real-time monitoring and artificial intelligence into manufacturing processes allows for improved precision and reduced costs, further driving market growth.

Growing Focus on Personalized Medicine

The shift toward personalized medicine is a major driver for the stem cell contract manufacturing market in Australia. Tailored stem cell therapies are gaining popularity for their ability to address individual patient needs, offering improved efficacy and reduced side effects. . For instance, Mesoblast, an Australian regenerative medicine company, is developing personalized stem cell therapies for conditions such as heart failure and chronic low back pain. This trend is particularly evident in areas such as oncology and regenerative medicine, where personalized treatments are proving transformative. Contract manufacturers are aligning their capabilities to support this demand by offering flexible production solutions and advanced technologies to cater to diverse therapeutic applications.

Market Trends:

Expansion of Allogenic Stem Cell Manufacturing

A significant trend in the Australia Stem Cell Contract Manufacturing Market is the growing focus on allogenic stem cell manufacturing. These stem cells, derived from donors and used in multiple patients, are becoming a preferred option due to their scalability and cost-effectiveness. For instance, Cell Therapies Pty Ltd, based in Melbourne, has been investing in bioprocessing technologies to enhance the efficiency and consistency of allogenic stem cell production. Manufacturers are increasingly investing in bioprocessing technologies to improve the efficiency and consistency of allogenic stem cell production. This approach aligns with the growing demand for standardized therapies that cater to large patient populations, particularly in treating chronic diseases like diabetes and cardiovascular conditions.

Integration of Automation and Advanced Bioprocessing Technologies

Automation and advancements in bioprocessing technologies are reshaping stem cell manufacturing in Australia. Contract manufacturers are adopting automated systems for cell expansion, monitoring, and quality control to reduce human intervention and improve production accuracy. For example, the University of Technology Sydney has developed a 3D printed system for harvesting stem cells from bioreactors, which offers high-quality, wide-scale production at a lower cost. Innovations such as closed-system bioreactors and machine learning applications for process optimization are gaining traction. These technologies not only enhance production efficiency but also ensure compliance with stringent regulatory standards, positioning Australia as a leader in advanced manufacturing practices for regenerative medicine.

Growing Demand for Induced Pluripotent Stem Cells (iPSCs)

The increasing adoption of induced pluripotent stem cells (iPSCs) marks another trend in the market. iPSCs, created by reprogramming adult cells, offer immense potential due to their ability to differentiate into various cell types while avoiding the ethical concerns associated with embryonic stem cells. For instance, Australian research institutes and biotech firms, such as the Monash University’s Biomedicine Discovery Institute, are at the forefront of exploring iPSC-based therapies for personalized medicine. Contract manufacturers are capitalizing on this demand by enhancing capabilities for iPSC production and providing tailored solutions for clinical and preclinical applications.

Rise in Cross-Border Collaborations

Cross-border collaborations are becoming more prevalent, with Australian firms partnering with international biopharmaceutical companies and research organizations. These partnerships facilitate knowledge exchange, access to advanced technologies, and global market reach. For instance, the University of Melbourne Stem Cell Network has collaborated with HOYA consulting to map the Australian cell and gene therapy landscape in a global context. Moreover, they align with Australia’s strategy to strengthen its presence in the global regenerative medicine landscape. The influx of foreign investments, combined with joint R&D initiatives, is accelerating the development of innovative stem cell therapies while fostering long-term growth for the contract manufacturing market.

Market Challenges Analysis:

High Cost of Stem Cell Manufacturing

The high cost associated with stem cell manufacturing is a significant challenge for the market. Advanced bioprocessing technologies, stringent regulatory requirements, and the need for specialized infrastructure contribute to elevated production costs. These expenses can limit access to stem cell therapies, particularly in resource-constrained settings, and present financial barriers for manufacturers attempting to scale operations.

Stringent Regulatory Framework

Australia’s rigorous regulatory landscape, while ensuring high standards and safety, poses challenges for market players. Complying with strict guidelines from bodies such as the Therapeutic Goods Administration (TGA) can be time-consuming and resource-intensive. The complexity of obtaining approvals for clinical trials and commercialization may deter smaller companies and delay product launches, impacting market growth.

Limited Skilled Workforce

A shortage of highly skilled professionals with expertise in stem cell bioprocessing and advanced manufacturing technologies is another major restraint. The specialized nature of the industry demands a workforce proficient in handling complex procedures, including cell culturing, cryopreservation, and quality control. This talent gap can slow down production timelines and hinder the market’s ability to meet growing demand.

Ethical and Logistical Concerns

Ethical considerations surrounding stem cell sourcing, particularly with human embryonic stem cells, pose challenges for manufacturers. Navigating these concerns while ensuring compliance with ethical guidelines can impact R&D activities. Additionally, logistical challenges, including cold chain management and transportation of stem cells, add complexity to supply chain operations and increase costs.

Market Opportunities:

The Australia Stem Cell Contract Manufacturing Market presents significant opportunities, driven by the rising prevalence of chronic and degenerative diseases such as diabetes, neurodegenerative disorders, and cardiovascular conditions. The increasing demand for innovative and personalized stem cell therapies offers immense growth potential for contract manufacturers. Australia’s strong research and development ecosystem, supported by world-class academic institutions and biotech hubs in cities like Sydney and Melbourne, creates a fertile ground for advancements in regenerative medicine. The integration of cutting-edge bioprocessing technologies, such as automation and scalable bioreactors, further enhances production capabilities, making it possible to meet the growing demand efficiently and cost-effectively.

Global collaborations and investments are expanding the market’s reach, as Australia’s stringent regulatory framework and emphasis on high-quality standards attract international stakeholders. The country’s focus on ethical practices and sustainability aligns with global trends, fostering trust and adoption of stem cell therapies. Additionally, emerging opportunities in areas such as allogenic and induced pluripotent stem cell (iPSC) manufacturing, driven by their scalability and versatility, position the market for long-term growth. As healthcare providers and biopharmaceutical companies increasingly seek reliable contract manufacturing partners, Australia is well-positioned to become a global leader in the production of advanced stem cell solutions. The market’s alignment with trends in personalized medicine and precision therapies ensures robust opportunities for innovation and expansion.

Market Segmentation Analysis:

The Australia Stem Cell Contract Manufacturing Market is segmented into various categories based on the scale of operation, size of contract manufacturer, source, type of stem cells, and end-users.

By Scale of Operation, the market is categorized into commercial, clinical, and preclinical operations. The commercial segment dominates due to the increasing production of stem cell-based therapies for large-scale distribution, while clinical and preclinical segments show steady growth driven by ongoing research and trials.

By Size of Contract Manufacturer, the market includes large/very large, mid-sized, and small-sized manufacturers. Large manufacturers lead due to their advanced infrastructure and ability to handle large-scale projects, whereas mid-sized and small-sized players cater to niche requirements, often focusing on innovative and personalized solutions.

By Source of Stem Cells, the market is divided into allogenic and autologous stem cells. Allogenic stem cells dominate, supported by their scalability and broader application potential, while autologous stem cells are preferred for personalized therapies.

By Type of Stem Cells, the segmentation includes adult stem cells (ASCs), human embryonic stem cells (HESCs), and induced pluripotent stem cells (iPSCs). ASCs lead the market owing to their established applications, while iPSCs are gaining traction for their versatility and ethical acceptability.

By End-User, the market is segmented into biopharmaceutical companies, research institutes, and others. Biopharmaceutical companies hold the largest share, driven by increasing partnerships with contract manufacturers, followed by research institutes leveraging stem cell technologies for innovation.

Segmentation:

By Scale of Operation

  • Commercial
  • Clinical
  • Preclinical

By Size of Contract Manufacturer

  • Large/Very Large
  • Mid-sized
  • Small-sized

By Source of Stem Cells

  • Allogenic
  • Autologous

By Type of Stem Cells

  • Adult Stem Cells (ASCs)
  • Human Embryonic Stem Cells (HESCs)
  • Induced Pluripotent Stem Cells (iPSCs)

By End-user

  • Biopharmaceutical companies
  • Research Institutes
  • Others

Regional Analysis:

The Australia Stem Cell Contract Manufacturing Market is marked by strong regional contributions driven by the presence of advanced research facilities, robust healthcare infrastructure, and growing biotechnology investments. Key regions contributing to the market include New South Wales, Victoria, Queensland, and Western Australia, each showcasing distinct strengths and opportunities.

New South Wales (38% market share):
New South Wales (NSW) holds the largest share in the market, benefiting from a concentration of biotech hubs and world-class research institutions in Sydney. The state’s advanced healthcare infrastructure and significant government funding for regenerative medicine drive its dominance. Key facilities such as the Garvan Institute of Medical Research and collaborations with global biopharmaceutical companies strengthen NSW’s position as a leader in stem cell contract manufacturing.

Victoria (32% market share):
Victoria is the second-largest contributor, with Melbourne as a hub for biotechnology and life sciences. The presence of leading institutions like the Murdoch Children’s Research Institute and the Australian Stem Cell Centre fosters innovation. Victoria’s focus on translational research and strong links between academia and industry ensure the development of cutting-edge stem cell therapies. The state’s supportive policies further encourage investments in stem cell manufacturing.

Queensland (18% market share):
Queensland’s contribution is significant, particularly in regenerative medicine and preclinical research. Brisbane is home to institutions like the Translational Research Institute and several contract manufacturers focusing on preclinical and clinical trial support. The state’s emphasis on collaborative research and investments in infrastructure make it a growing center for stem cell development.

Western Australia (8% market share):
Western Australia has a smaller but growing share in the market, driven by initiatives to strengthen its biotechnology sector. Perth hosts emerging players in stem cell research and manufacturing, focusing on niche areas such as autologous stem cell therapies.

Other Regions (4% market share):
Other regions, including South Australia and Tasmania, contribute modestly but show potential for growth. These regions are benefiting from increased focus on research funding and cross-state collaborations in regenerative medicine.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Key Player Analysis

  •         WuXi AppTec
  •          Boehringer Ingelheim
  •          Catalent Inc.
  •          Cytiva
  •          AbbVie Inc.
  •          AGC Biologics
  •          FUJIFILM Diosynth Biotechnologies
  •         Samsung Biologics
  •         Thermo Fisher Scientific Inc.
  •         Cytovance Biologics

Competitive Analysis:

The Australia Stem Cell Contract Manufacturing Market is characterized by a competitive landscape with key players leveraging advanced technologies and strategic collaborations to gain market share. Leading contract manufacturers in the country focus on providing scalable and high-quality solutions for biopharmaceutical companies, research institutions, and other end-users. The market is highly fragmented, with a mix of large global players and emerging domestic companies. Global manufacturers dominate due to their robust infrastructure, extensive expertise, and ability to handle large-scale operations. Meanwhile, mid-sized and smaller firms carve out niches by offering specialized and personalized manufacturing services, particularly in preclinical and clinical trials. For instance, collaboration between academic institutions, biotech companies, and manufacturers is a defining feature, fostering innovation and accelerating commercialization. The competitive environment is further influenced by advancements in bioprocessing technologies, a strong focus on ethical standards, and compliance with stringent regulatory frameworks, positioning Australia as a leader in the global stem cell manufacturing sector.

Recent Developments:

  • On January 21, 2025, Catalent announced a strategic collaboration with Galapagos NV to support decentralized manufacturing for clinical studies of GLPG5101, Galapagos’ investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma. Catalent’s facility in Princeton, New Jersey, will facilitate this manufacturing, aiming to bring the process closer to cancer treatment centers, potentially reducing the time from vein-to-vein to seven days.
  • On January 9, 2025, FUJIFILM Diosynth Biotechnologies celebrated the expansion of its production facility in Hillerød, Denmark. This expansion increases the site’s capacity from six to twelve bioreactors for mammalian cell culture, making it the largest end-to-end biopharmaceutical manufacturing site in Europe. The expansion reflects FUJIFILM’s commitment to supporting clients and patients worldwide with timely delivery of critical therapies

Market Concentration & Characteristics:

The Australia Stem Cell Contract Manufacturing Market exhibits a moderately fragmented structure, with a blend of established global players and emerging domestic manufacturers. The presence of globally recognized biopharmaceutical companies and specialized local firms drives a dynamic competitive environment. Large players dominate the commercial-scale segment, leveraging advanced technologies and extensive infrastructure, while smaller and mid-sized firms focus on niche offerings, such as preclinical and clinical trial support. The market is characterized by strong research collaborations among academic institutions, biotech firms, and contract manufacturers, fostering innovation and accelerating product development. Australia’s stringent regulatory framework ensures high-quality production standards and ethical compliance, attracting global investments. Additionally, advancements in bioprocessing technologies and the integration of automation enhance manufacturing efficiency and scalability. With a growing emphasis on personalized medicine, the market displays significant potential for further specialization and expansion, solidifying Australia’s position in the global stem cell manufacturing landscape.

Report Coverage:

The research report offers an in-depth analysis based on By Scale of Operation, By Size of Contract Manufacturer, By Source of Stem Cells, By Type of Stem Cells and By End-user. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook:

  • The market is anticipated to witness significant growth over the forecast period, driven by rising demand for advanced stem cell therapies.
  • Increasing collaborations between biotech firms, academic institutions, and contract manufacturers will enhance R&D capabilities.
  • Government support through funding programs and streamlined regulatory frameworks will continue to encourage innovation and commercialization.
  • The adoption of cutting-edge bioprocessing technologies will improve production efficiency and scalability.
  • Personalized medicine advancements will drive the demand for customized stem cell manufacturing solutions.
  • Strategic partnerships with global markets in Asia, Europe, and North America will bolster Australia’s competitive edge.
  • Expansion of biotech hubs in Sydney, Melbourne, and Brisbane will strengthen the regional infrastructure for manufacturing.
  • Growing investments in ethical practices and high-quality production standards will reinforce global trust in Australian products.
  • The market will witness increased utilization of automation and AI to optimize manufacturing processes.
  • Rising awareness of regenerative medicine will create new opportunities for market players in emerging therapeutic areas.

CHAPTER NO. 1 : INTRODUCTION 19

1.1. Report Description 19

Purpose of the Report 19

USP & Key Offerings 19

1.2. Key Benefits for Stakeholders 19

1.3. Target Audience 20

1.4. Report Scope 20

CHAPTER NO. 2 : EXECUTIVE SUMMARY 21

2.1. Australia Stem Cell Contract Manufacturing Market Snapshot 21

2.2. Australia Stem Cell Contract Manufacturing Market, 2018 – 2032 (USD Million) 22

CHAPTER NO. 3 : AUSTRALIA STEM CELL CONTRACT MANUFACTURING MARKET – INDUSTRY ANALYSIS 23

3.1. Introduction 23

3.2. Market Drivers 24

3.3. Supportive Regulatory Framework 24

3.4. Demand for Specialized Manufacturing Expertise 25

3.5. Market Restraints 26

3.6. Regulatory Complexity 26

3.7. Market Opportunities 27

3.8. Market Opportunity Analysis 27

3.9. Porter’s Five Forces Analysis 28

CHAPTER NO. 4 : ANALYSIS COMPETITIVE LANDSCAPE 29

4.1. Company Market Share Analysis – 2023 29

4.1.1. Australia Stem Cell Contract Manufacturing Market: Company Market Share, by Volume, 2023 29

4.1.2. Australia Stem Cell Contract Manufacturing Market: Company Market Share, by Revenue, 2023 30

4.1.3. Australia Stem Cell Contract Manufacturing Market: Top 6 Company Market Share, by Revenue, 2023 30

4.1.4. Australia Stem Cell Contract Manufacturing Market: Top 3 Company Market Share, by Revenue, 2023 31

4.2. Australia Stem Cell Contract Manufacturing Market Company Revenue Market Share, 2023 32

4.3. Company Assessment Metrics, 2023 33

4.3.1. Stars 33

4.3.2. Emerging Leaders 33

4.3.3. Pervasive Players 33

4.3.4. Participants 33

4.4. Start-ups /SMEs Assessment Metrics, 2023 33

4.4.1. Progressive Companies 33

4.4.2. Responsive Companies 33

4.4.3. Dynamic Companies 33

4.4.4. Starting Blocks 33

4.5. Strategic Developments 34

4.5.1. Acquisitions & Mergers 34

New Product Launch 34

Regional Expansion 34

4.6. Key Players Product Matrix 35

CHAPTER NO. 5 : PESTEL & ADJACENT MARKET ANALYSIS 36

5.1. PESTEL 36

5.1.1. Political Factors 36

5.1.2. Economic Factors 36

5.1.3. Social Factors 36

5.1.4. Technological Factors 36

5.1.5. Environmental Factors 36

5.1.6. Legal Factors 36

5.2. Adjacent Market Analysis 36

CHAPTER NO. 6 : AUSTRALIA STEM CELL CONTRACT MANUFACTURING MARKET – BY SCALE OF OPERATION SEGMENT ANALYSIS 37

6.1. Australia Stem Cell Contract Manufacturing Market Overview, by Scale of Operation Segment 37

6.1.1. Australia Stem Cell Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 38

6.1.2. Australia Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Scale of Operation 39

6.1.3. Incremental Revenue Growth Opportunity, by Scale of Operation, 2024 – 2032 39

6.1.4. Australia Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 40

6.2. Commercial 41

6.3. Clinical 42

6.4. Preclinical 43

CHAPTER NO. 7 : AUSTRALIA STEM CELL CONTRACT MANUFACTURING MARKET – BY SIZE OF CONTRACT MANUFACTURER SEGMENT ANALYSIS 44

7.1. Australia Stem Cell Contract Manufacturing Market Overview, by Size of Contract Manufacturer Segment 44

7.1.1. Australia Stem Cell Contract Manufacturing Market Revenue Share, By Size of Contract Manufacturer, 2023 & 2032 45

7.1.2. Australia Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Size of Contract Manufacturer 46

7.1.3. Incremental Revenue Growth Opportunity, by Size of Contract Manufacturer, 2024 – 2032 46

7.1.4. Australia Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018, 2023, 2027 & 2032 47

7.2. Large/Very Large 48

7.3. Mid-sized 49

7.4. Small-sized 50

CHAPTER NO. 8 : AUSTRALIA STEM CELL CONTRACT MANUFACTURING MARKET – BY END-USER SEGMENT ANALYSIS 51

8.1. Australia Stem Cell Contract Manufacturing Market Overview, by End-user Segment 51

8.1.1. Australia Stem Cell Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 52

8.1.2. Australia Stem Cell Contract Manufacturing Market Attractiveness Analysis, By End-user 53

8.1.3. Incremental Revenue Growth Opportunity, by End-user, 2024 – 2032 53

8.1.4. Australia Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 54

8.2. Biopharmaceutical companies 55

8.3. Research Institutes 56

8.4. Others 57

CHAPTER NO. 9 : AUSTRALIA STEM CELL CONTRACT MANUFACTURING MARKET – BY SOURCE OF STEM CELLS SEGMENT ANALYSIS 58

9.1. Australia Stem Cell Contract Manufacturing Market Overview, by Source of Stem Cells Segment 58

9.1.1. Australia Stem Cell Contract Manufacturing Market Revenue Share, By Source of Stem Cells, 2023 & 2032 59

9.1.2. Australia Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Source of Stem Cells 60

9.1.3. Incremental Revenue Growth Opportunity, by Source of Stem Cells, 2024 – 2032 60

9.1.4. Australia Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018, 2023, 2027 & 2032 61

9.2. Allogenic 62

9.3. Autologous 63

CHAPTER NO. 10 : AUSTRALIA STEM CELL CONTRACT MANUFACTURING MARKET – BY TYPE OF STEM CELLS SEGMENT ANALYSIS 64

10.1. Australia Stem Cell Contract Manufacturing Market Overview, by Type of Stem Cells Segment 64

10.1.1. Australia Stem Cell Contract Manufacturing Market Revenue Share, By Type of Stem Cells, 2023 & 2032 65

10.1.2. Australia Stem Cell Contract Manufacturing Market Attractiveness Analysis, By Type of Stem Cells 66

10.1.3. Incremental Revenue Growth Opportunity, by Type of Stem Cells, 2024 – 2032 66

10.1.4. Australia Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018, 2023, 2027 & 2032 67

10.2. Adult Stem Cells (ASCs) 68

10.3. Human Embryonic Stem Cells (HESCs) 69

10.4. Induced Pluripotent Stem Cells (iPSCs) 70

CHAPTER NO. 11 : STEM CELL CONTRACT MANUFACTURING MARKET – ANALYSIS 71

11.1.1. Australia Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 71

11.1.2. Australia Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018 – 2023 (USD Million) 72

11.1.3. Australia Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 73

11.1.4. Australia Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018 – 2023 (USD Million) 74

11.1.5. Australia Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018 – 2023 (USD Million) 75

CHAPTER NO. 12 : COMPANY PROFILES 76

12.1. Lonza Group 76

12.1.1. Company Overview 76

12.1.2. Product Portfolio 76

12.1.3. Swot Analysis 76

12.1.4. Business Strategy 77

12.1.5. Financial Overview 77

12.2. WuXi AppTec 78

12.3. Boehringer Ingelheim 78

12.4. Catalent Inc. 78

12.5. Cytiva 78

12.6. AbbVie Inc. 78

12.7. AGC Biologics 78

12.8. FUJIFILM Diosynth Biotechnologies 78

12.9. Samsung Biologics 78

12.10. Thermo Fisher Scientific Inc. 78

12.11. Cytovance Biologics 78

List of Figures

FIG NO. 1. Australia Stem Cell Contract Manufacturing Market Revenue, 2018 – 2032 (USD Million) 22

FIG NO. 2. Porter’s Five Forces Analysis for Australia Stem Cell Contract Manufacturing Market 28

FIG NO. 3. Company Share Analysis, 2023 29

FIG NO. 4. Company Share Analysis, 2023 30

FIG NO. 5. Company Share Analysis, 2023 30

FIG NO. 6. Company Share Analysis, 2023 31

FIG NO. 7. Australia Stem Cell Contract Manufacturing Market – Company Revenue Market Share, 2023 32

FIG NO. 8. Australia Stem Cell Contract Manufacturing Market Revenue Share, By Scale of Operation, 2023 & 2032 38

FIG NO. 9. Market Attractiveness Analysis, By Scale of Operation 39

FIG NO. 10. Incremental Revenue Growth Opportunity by Scale of Operation, 2024 – 2032 39

FIG NO. 11. Australia Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018, 2023, 2027 & 2032 40

FIG NO. 12. Australia Stem Cell Contract Manufacturing Market for Commercial, Revenue (USD Million) 2018 – 2032 41

FIG NO. 13. Australia Stem Cell Contract Manufacturing Market for Clinical, Revenue (USD Million) 2018 – 2032 42

FIG NO. 14. Australia Stem Cell Contract Manufacturing Market for Preclinical, Revenue (USD Million) 2018 – 2032 43

FIG NO. 15. Australia Stem Cell Contract Manufacturing Market Revenue Share, By Size of Contract Manufacturer, 2023 & 2032 45

FIG NO. 16. Market Attractiveness Analysis, By Size of Contract Manufacturer 46

FIG NO. 17. Incremental Revenue Growth Opportunity by Size of Contract Manufacturer, 2024 – 2032 46

FIG NO. 18. Australia Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018, 2023, 2027 & 2032 47

FIG NO. 19. Australia Stem Cell Contract Manufacturing Market for Large/Very Large, Revenue (USD Million) 2018 – 2032 48

FIG NO. 20. Australia Stem Cell Contract Manufacturing Market for Mid-sized, Revenue (USD Million) 2018 – 2032 49

FIG NO. 21. Australia Stem Cell Contract Manufacturing Market for Small-sized, Revenue (USD Million) 2018 – 2032 50

FIG NO. 22. Australia Stem Cell Contract Manufacturing Market Revenue Share, By End-user, 2023 & 2032 52

FIG NO. 23. Market Attractiveness Analysis, By End-user 53

FIG NO. 24. Incremental Revenue Growth Opportunity by End-user, 2024 – 2032 53

FIG NO. 25. Australia Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018, 2023, 2027 & 2032 54

FIG NO. 26. Australia Stem Cell Contract Manufacturing Market for Biopharmaceutical companies, Revenue (USD Million) 2018 – 2032 55

FIG NO. 27. Australia Stem Cell Contract Manufacturing Market for Research Institutes, Revenue (USD Million) 2018 – 2032 56

FIG NO. 28. Australia Stem Cell Contract Manufacturing Market for Others, Revenue (USD Million) 2018 – 2032 57

FIG NO. 29. Australia Stem Cell Contract Manufacturing Market Revenue Share, By Source of Stem Cells, 2023 & 2032 59

FIG NO. 30. Market Attractiveness Analysis, By Source of Stem Cells 60

FIG NO. 31. Incremental Revenue Growth Opportunity by Source of Stem Cells, 2024 – 2032 60

FIG NO. 32. Australia Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018, 2023, 2027 & 2032 61

FIG NO. 33. Australia Stem Cell Contract Manufacturing Market for Allogenic, Revenue (USD Million) 2018 – 2032 62

FIG NO. 34. Australia Stem Cell Contract Manufacturing Market for Autologous, Revenue (USD Million) 2018 – 2032 63

FIG NO. 35. Australia Stem Cell Contract Manufacturing Market Revenue Share, By Type of Stem Cells, 2023 & 2032 65

FIG NO. 36. Market Attractiveness Analysis, By Type of Stem Cells 66

FIG NO. 37. Incremental Revenue Growth Opportunity by Type of Stem Cells, 2024 – 2032 66

FIG NO. 38. Australia Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018, 2023, 2027 & 2032 67

FIG NO. 39. Australia Stem Cell Contract Manufacturing Market for Adult Stem Cells (ASCs), Revenue (USD Million) 2018 – 2032 68

FIG NO. 40. Australia Stem Cell Contract Manufacturing Market for Human Embryonic Stem Cells (HESCs), Revenue (USD Million) 2018 – 2032 69

FIG NO. 41. Australia Stem Cell Contract Manufacturing Market for Induced Pluripotent Stem Cells (iPSCs), Revenue (USD Million) 2018 – 2032 70

List of Tables

TABLE NO. 1. : Australia Stem Cell Contract Manufacturing Market: Snapshot 21

TABLE NO. 2. : Drivers for the Australia Stem Cell Contract Manufacturing Market: Impact Analysis 24

TABLE NO. 3. : Restraints for the Australia Stem Cell Contract Manufacturing Market: Impact Analysis 26

TABLE NO. 4. : Australia Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2018 – 2023 (USD Million) 71

TABLE NO. 5. : Australia Stem Cell Contract Manufacturing Market Revenue, By Scale of Operation, 2024 – 2032 (USD Million) 71

TABLE NO. 6. : Australia Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2018 – 2023 (USD Million) 72

TABLE NO. 7. : Australia Stem Cell Contract Manufacturing Market Revenue, By Size of Contract Manufacturer, 2024 – 2032 (USD Million) 72

TABLE NO. 8. : Australia Stem Cell Contract Manufacturing Market Revenue, By End-user, 2018 – 2023 (USD Million) 73

TABLE NO. 9. : Australia Stem Cell Contract Manufacturing Market Revenue, By End-user, 2024 – 2032 (USD Million) 73

TABLE NO. 10. : Australia Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2018 – 2023 (USD Million) 74

TABLE NO. 11. : Australia Stem Cell Contract Manufacturing Market Revenue, By Source of Stem Cells, 2024 – 2032 (USD Million) 74

TABLE NO. 12. : Australia Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2018 – 2023 (USD Million) 75

TABLE NO. 13. : Australia Stem Cell Contract Manufacturing Market Revenue, By Type of Stem Cells, 2024 – 2032 (USD Million) 75

 

Frequently Asked Questions

What is the projected growth of the Australia Stem Cell Contract Manufacturing Market?

The market is expected to grow from USD 22.27 million in 2024 to USD 60.24 million by 2032, with a CAGR of 13.25%.

What factors are driving the growth of this market?

Key drivers include the increasing prevalence of chronic and degenerative diseases, supportive government initiatives, advancements in bioprocessing technologies, and a strong research and development ecosystem.

How is Australia positioned in the global stem cell manufacturing industry?

Australia is strategically positioned as a hub in the Asia-Pacific region, with advanced research facilities, a skilled workforce, and favorable policies that attract global collaborations and investments.

What challenges does the Australia Stem Cell Contract Manufacturing Market face?

Challenges include the high cost of stem cell therapies, stringent regulatory requirements, and the need for skilled personnel to manage advanced manufacturing processes.

Australia Enterprise Monitoring Market

Published:
Report ID: 75492

Australia AC-DC Power Supply in Data Center Market

Published:
Report ID: 74869

Australia Data Center Filters Market

Published:
Report ID: 74721

Australia Occupational Health Market

Published:
Report ID: 61938

Australia Grid Modernization Market

Published:
Report ID: 73498

Australia Data Center Security Market

Published:
Report ID: 73460

Australia Data Center Processor Market

Published:
Report ID: 73239

Australia Building Decoration Market

Published:
Report ID: 72997

Australia Industry Vertical Modernization Services Market

Published:
Report ID: 72975

MEA Biologics and Biosimilars Market

Published:
Report ID: 75183

Cell Regeneration Medicine Market

Published:
Report ID: 74708

Antisense Oligonucleotides Market

Published:
Report ID: 74051

Cell Culture Sampling Devices Market

Published:
Report ID: 73920

Cell and Gene Therapy Manufacturing Market

Published:
Report ID: 73917

Capsule Endoscope and Workstation Market

Published:
Report ID: 20339

Australia Occupational Health Market

Published:
Report ID: 61938

Rapid Microbiology Testing Market

Published:
Report ID: 73613

UK Stem Cell Contract Manufacturing Market

Published:
Report ID: 72565

U.S. Stem Cell Contract Manufacturing Market

Published:
Report ID: 72553

Middle East Stem Cell Contract Manufacturing Market

Published:
Report ID: 72494

Mexico Stem Cell Contract Manufacturing Market

Published:
Report ID: 72483

Purchase Options

The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$2699

To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$3699

The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
$5699

Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN